iPSC-Derived Neural Stem Cells for Epilepsy Studies
Using our expertise in reprogramming and neural induction, Axol has differentiated neural stem cells from iPSCs derived from a patient that was clinically diagnosed with epilepsy. Our latest blog discusses the need for human iPSC-derived neural cell models from healthy and patient donors to help further our understanding of neuronal networks and identify effective treatments for conditions such as epilepsy.
Axol Human iPSC-Derived Neural Stem Cells
Axol Human iPSC-Derived Neural Stem Cells (NSCs) are derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined neural induction conditions. The NSCs express typical markers of cerebral cortical neural stem and progenitor cells such as PAX6, FOXG1 and nestin, and spontaneously form polarized neural tube-like rosette structures when plated as a monolayer in culture (see below).
Additionally, Axol NSCs are capable of generating a spectrum of cerebral cortical excitatory and inhibitory neurons that are electrically active and have the ability to form functional synapses and circuits in vitro.
After thawing and plating, the neural stem cells terminally differentiate to acquire mature electrophysiological properties, and form functional synaptic networks over a period of 40 ~ 50 days. Axol NSCs are easy to differentiate to neurons or mixed neural cell types, following our protocols and using our tailored media and reagent bundles.
A highly pure population of neurons can be generated from Axol NSCs following the synchronous differentiation protocol. Using our specialized coating reagents, neurons derived from Axol NSCs can be maintained in culture long-term (>1 year). NSCs are available from multiple donors to suit your research needs and have been characterized extensively.
|Donor age at sampling
|Donor age of onset
||Monolayer & chemically defined medium
||≥1.5 million cells
||1 vial of Neural Stem Cells (≥1.5 million cells) and 1 bottle of Neural Plating-XF Medium (30 mL)
||iPSC-derived neural stem cells
||The patient presented with prenatal (3-4 weeks before delivery) tremors in utero. After birth, the patient exhibited bradycardia, abnormal EEG (central apneas present) and earlymyoclonic encephalopathy. The patient's epilepsy was characterized further by: noted erratic seizures (1 to 5 per day), poor oral and motor skills, inability to follow with gaze and the brainstem auditory evoked response (BAER) revealed only waveforms I and III suggestive of upper pontine dysfunction. The donor was treated with phenobarbital and Klonopin.